477 related articles for article (PubMed ID: 24251786)
1. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.
Xue X; Mutyam V; Tang L; Biswas S; Du M; Jackson LA; Dai Y; Belakhov V; Shalev M; Chen F; Schacht J; J Bridges R; Baasov T; Hong J; Bedwell DM; Rowe SM
Am J Respir Cell Mol Biol; 2014 Apr; 50(4):805-16. PubMed ID: 24251786
[TBL] [Abstract][Full Text] [Related]
2. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
Mutyam V; Sharma J; Li Y; Peng N; Chen J; Tang LP; Falk Libby E; Singh AK; Conrath K; Rowe SM
Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.
Mutyam V; Libby EF; Peng N; Hadjiliadis D; Bonk M; Solomon GM; Rowe SM
J Cyst Fibros; 2017 Jan; 16(1):24-29. PubMed ID: 27707539
[TBL] [Abstract][Full Text] [Related]
4. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54.
Rowe SM; Sloane P; Tang LP; Backer K; Mazur M; Buckley-Lanier J; Nudelman I; Belakhov V; Bebok Z; Schwiebert E; Baasov T; Bedwell DM
J Mol Med (Berl); 2011 Nov; 89(11):1149-61. PubMed ID: 21779978
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.
Mutyam V; Du M; Xue X; Keeling KM; White EL; Bostwick JR; Rasmussen L; Liu B; Mazur M; Hong JS; Falk Libby E; Liang F; Shang H; Mense M; Suto MJ; Bedwell DM; Rowe SM
Am J Respir Crit Care Med; 2016 Nov; 194(9):1092-1103. PubMed ID: 27104944
[TBL] [Abstract][Full Text] [Related]
6. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
[TBL] [Abstract][Full Text] [Related]
7. The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators.
Chen J; Thrasher K; Fu L; Wang W; Aghamohammadzadeh S; Wen H; Tang L; Keeling KM; Falk Libby E; Bedwell DM; Rowe SM
Am J Physiol Lung Cell Mol Physiol; 2023 Jun; 324(6):L756-L770. PubMed ID: 37014818
[TBL] [Abstract][Full Text] [Related]
8. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
9. Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model.
Du M; Keeling KM; Fan L; Liu X; Bedwell DM
J Biol Chem; 2009 Mar; 284(11):6885-92. PubMed ID: 19136563
[TBL] [Abstract][Full Text] [Related]
10. Ataluren/ivacaftor combination therapy: Two N-of-1 trials in cystic fibrosis patients with nonsense mutations.
Peabody Lever JE; Mutyam V; Hathorne HY; Peng N; Sharma J; Edwards LJ; Rowe SM
Pediatr Pulmonol; 2020 Jul; 55(7):1838-1842. PubMed ID: 32281737
[TBL] [Abstract][Full Text] [Related]
11. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.
Van Goor F; Yu H; Burton B; Hoffman BJ
J Cyst Fibros; 2014 Jan; 13(1):29-36. PubMed ID: 23891399
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
[TBL] [Abstract][Full Text] [Related]
13. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model.
Du M; Liu X; Welch EM; Hirawat S; Peltz SW; Bedwell DM
Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2064-9. PubMed ID: 18272502
[TBL] [Abstract][Full Text] [Related]
14. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
[TBL] [Abstract][Full Text] [Related]
15. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic therapy for stop mutations: how much CFTR activity is enough?
Kerem E
Curr Opin Pulm Med; 2004 Nov; 10(6):547-52. PubMed ID: 15510065
[TBL] [Abstract][Full Text] [Related]
17. Restoration of W1282X CFTR activity by enhanced expression.
Rowe SM; Varga K; Rab A; Bebok Z; Byram K; Li Y; Sorscher EJ; Clancy JP
Am J Respir Cell Mol Biol; 2007 Sep; 37(3):347-56. PubMed ID: 17541014
[TBL] [Abstract][Full Text] [Related]
18. Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model.
Du M; Keeling KM; Fan L; Liu X; Kovaçs T; Sorscher E; Bedwell DM
J Mol Med (Berl); 2006 Jul; 84(7):573-82. PubMed ID: 16541275
[TBL] [Abstract][Full Text] [Related]
19. Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.
Phuan PW; Son JH; Tan JA; Li C; Musante I; Zlock L; Nielson DW; Finkbeiner WE; Kurth MJ; Galietta LJ; Haggie PM; Verkman AS
J Cyst Fibros; 2018 Sep; 17(5):595-606. PubMed ID: 29903467
[TBL] [Abstract][Full Text] [Related]
20. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
